{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:37:33Z","timestamp":1793972253420,"version":"4.8.0"},"reference-count":217,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaad.2021.10.066","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:20:53Z","timestamp":1643973653000},"page":"957-978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Systemic sclerosis in adults. Part II: management and therapeutics"],"prefix":"10.1016","volume":"87","author":[{"given":"Rebekka","family":"Jerjen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2021.10.066_bib1","series-title":"Systemic Sclerosis","first-page":"129","article-title":"Cutaneous involvement in systemic sclerosis","author":"Clements","year":"2004"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib2","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib3","first-page":"84","article-title":"The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J Rheumatol"},{"issue":"2 suppl 58","key":"10.1016\/j.jaad.2021.10.066_bib4","first-page":"S37","article-title":"Repeated teaching courses of the modified Rodnan skin score in systemic sclerosis","volume":"28","author":"Ionescu","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/ard.2006.066530","article-title":"The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis","volume":"66","author":"Czirj\u00e1k","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1756-185X.12106","article-title":"A systematic review of ultrasonography as an outcome measure of skin involvement in systemic sclerosis","volume":"16","author":"Ch\u2019ng","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.22093","article-title":"Durometry for the assessment of skin disease in systemic sclerosis","volume":"55","author":"Kissin","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/art.23564","article-title":"Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial","volume":"59","author":"Merkel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s42358-020-00152-6","article-title":"Durometry as an alternative tool to the modified Rodnan\u2019s skin score in the assessment of diffuse systemic sclerosis patients: A cross-sectional study","volume":"60","author":"De Oliveira","year":"2020","journal-title":"Adv Rheumatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib10","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00296-011-1993-9","article-title":"The correlation between durometer score and modified Rodnan skin score in systemic sclerosis","volume":"32","author":"Moon","year":"2012","journal-title":"Rheumatol Int"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2021.10.066_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0190-9622(96)90601-5","article-title":"Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma","volume":"35","author":"Enomoto","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201440","article-title":"A novel ultra-light suction device for mechanical characterization of skin","volume":"13","author":"M\u00fcller","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-020-02214-y","article-title":"Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis","volume":"22","author":"M\u00fcller","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4103\/0378-6323.86481","article-title":"Dermatology life quality index in Thai patients with systemic sclerosis: a cross-sectional study","volume":"77","author":"Chularojanamontri","year":"2011","journal-title":"Indian J DermatolVenereol Leprol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2016-210534","article-title":"Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis","volume":"76","author":"Man","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/art.21084","article-title":"The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties","volume":"53","author":"Johnson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13075-020-02329-2","article-title":"Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database","volume":"22","author":"Allanore","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the Health Assessment Questionnaire and special patient- generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.autrev.2015.07.012","article-title":"Quality of life in systemic sclerosis","volume":"14","author":"Almeida","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/rheumatology\/kew003","article-title":"The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis","volume":"55","author":"Ziemek","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib22","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2021.10.066_bib23","first-page":"1207.2","article-title":"SAT0262 modified ACR composite response index in systemic sclerosis score shows sensitivity and external validation to measure magnitude of response at 12 months in diffuse cutaneous systemic sclerosis","volume":"vol 8","author":"Abignano","year":"2019"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.semarthrit.2016.07.010","article-title":"Measures of disease status in systemic sclerosis: a systematic review","volume":"46","author":"Tay","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"5 suppl 100","key":"10.1016\/j.jaad.2021.10.066_bib25","first-page":"186","article-title":"Disease activity indices in systemic sclerosis: a systematic literature review","volume":"34","author":"Melsens","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib26","doi-asserted-by":"crossref","first-page":"rkz044","DOI":"10.1093\/rap\/rkz044","article-title":"The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review","volume":"3","author":"Liem","year":"2019","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/phpp.12185","article-title":"Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients","volume":"31","author":"Connolly","year":"2015","journal-title":"PhotodermatolPhotoimmunol Photomed"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000445821","article-title":"Improvement of microstomia in scleroderma after carbon dioxide laser treatment","volume":"8","author":"Bennani","year":"2016","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/14764172.2012.672744","article-title":"Improvement of microstomia in scleroderma after intense pulsed light: a case series of four patients","volume":"14","author":"Comstedt","year":"2012","journal-title":"J Cosmet Laser Ther"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14764172.2016.1262961","article-title":"Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study","volume":"19","author":"Rosholm Comstedt","year":"2017","journal-title":"J Cosmet Laser Ther"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00300808","article-title":"Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study","volume":"14","author":"Sharada","year":"1994","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-4362.1995.tb04664.x","article-title":"Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis","volume":"34","author":"Pai","year":"1995","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2019.07.006","article-title":"Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature","volume":"82","author":"Traineau","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/clc.20865","article-title":"Association of warfarin use with valvular and vascular calcification: a review","volume":"34","author":"Palaniswamy","year":"2011","journal-title":"Clin Cardiol"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib35","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis","volume":"47","author":"De Vries-Bouwstra","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.jaad.2021.10.066_bib41","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib42","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in Scleroderma Lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"Van Den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jaad.2021.10.066_bib45","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"9790","key":"10.1016\/j.jaad.2021.10.066_bib46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib47","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.bbmt.2017.01.012","article-title":"Myeloablative autologous transplantation of CD34 + selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CY) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial","volume":"23","author":"Sullivan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9872","key":"10.1016\/j.jaad.2021.10.066_bib49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/BOR.0000000000000541","article-title":"Hematopoietic stem-cell transplantation in systemic sclerosis: an update","volume":"30","author":"Spierings","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib51","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib52","doi-asserted-by":"crossref","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib54","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2 suppl 71","key":"10.1016\/j.jaad.2021.10.066_bib56","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.120778","article-title":"Two-year Results of an Open Pilot Study of a 2-treatment Course with rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib59","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib60","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib61","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"4 suppl 113","key":"10.1016\/j.jaad.2021.10.066_bib63","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"87","key":"10.1016\/j.jaad.2021.10.066_bib64","doi-asserted-by":"crossref","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of rituximab in systemic sclerosis: A systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib65","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib66","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1038\/jid.2012.226","article-title":"IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease","volume":"132","author":"Le Huu","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib68","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib70","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"10.1016\/j.jaad.2021.10.066_bib71","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib72","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10038","key":"10.1016\/j.jaad.2021.10.066_bib73","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212489","article-title":"Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators","volume":"77","author":"Matei","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib77","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib78","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib79","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib81","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib82","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An Open-label, Phase II Study of the Safety and Tolerability of pirfenidone in Patients with Scleroderma-associated interstitial Lung Disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib83","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib84","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib85","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.10.066_bib86","series-title":"Wednesday, 13 June 2018","article-title":"OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001","author":"Spiera","year":"2018"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib87","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-\u03b3 agonist triterpenoid ameliorates experimental fibrosis: PPAR-\u03b3-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib88","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","article-title":"Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension","volume":"76","author":"Avouac","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib90","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"suppl 10","key":"10.1016\/j.jaad.2021.10.066_bib92","article-title":"Tofacitinib in early diffuse cutaneous systemic sclerosis\u2014results of Phase I\/II investigator-initiated, double-blind randomized placebo-controlled trial [abstract]","volume":"71","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib93","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3727\/096368912X639017","article-title":"Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis","volume":"22","author":"Scuderi","year":"2013","journal-title":"Cell Transplant"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/rheumatology\/kev323","article-title":"Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up","volume":"55","author":"Guillaume-Jugnot","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib95","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2014-205681","article-title":"Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial","volume":"74","author":"Granel","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1-3","key":"10.1016\/j.jaad.2021.10.066_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0300-483X(00)00272-9","article-title":"Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis","volume":"155","author":"Gabriele","year":"2000","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib98","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib99","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib100","doi-asserted-by":"crossref","first-page":"389582","DOI":"10.1155\/2014\/389582","article-title":"Oxidative damage and antioxidative therapy in systemic sclerosis","volume":"2014","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib101","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.freeradbiomed.2004.09.032","article-title":"Effects of short-term treatment with vitamin E in systemic sclerosis: A double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement","volume":"38","author":"Cracowski","year":"2005","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib102","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib103","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud\u2019s phenomenon\u2014an update on diagnosis, classification and management","volume":"38","author":"Pauling","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib104","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib105","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib106","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib107","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.44.1.30","article-title":"A randomised double-blind trial of diltiazem in the treatment of Raynaud\u2019s phenomenon","volume":"44","author":"Kahan","year":"1985","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib109","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"10.1016\/j.jaad.2021.10.066_bib110","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"4 suppl 106","key":"10.1016\/j.jaad.2021.10.066_bib111","first-page":"151","article-title":"Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study","volume":"35","author":"Andrigueti","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib112","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib113","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1113\/expphysiol.2007.038588","article-title":"Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium","volume":"93","author":"Mitchell","year":"2008","journal-title":"Exp Physiol"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib114","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud\u2019s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib116","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib117","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib118","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1997.00219.x","article-title":"The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud\u2019s phenomenon","volume":"242","author":"Pancera","year":"1997","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib119","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1345\/aph.1H201","article-title":"Renin\u2014angiotensin system mediators and Raynaud\u2019s phenomenon","volume":"40","author":"Wood","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","article-title":"Subjective and objective assessment of enalapril in primary Raynaud\u2019s phenomenon","volume":"31","author":"Challenor","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib121","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1987.tb07356.x","article-title":"The effect of captopril on cutaneous blood flow in patients with primary Raynaud\u2019s phenomenon","volume":"117","author":"Rustin","year":"1987","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib122","first-page":"37","article-title":"Treatment of Raynaud\u2019s phenomenon with captopril","volume":"13","author":"Tosi","year":"1987","journal-title":"Drugs Exp Clin Res"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib123","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","article-title":"Enalapril in Raynaud\u2019s phenomenon","volume":"13","author":"Janini","year":"1988","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib124","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","article-title":"Trial of platelet-inhibiting drug in scleroderma double-blind study with dipyridamole and aspirin","volume":"27","author":"Beckett","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib125","first-page":"499","article-title":"Long-term low molecular weight heparin therapy for severe Raynaud\u2019s phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib126","first-page":"CD000956","article-title":"Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2021.10.066_bib127","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0093-3619(09)79298-6","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers","volume":"2009","author":"Thiers","year":"2009","journal-title":"Yearbook of Dermatology and Dermatologic Surgery"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib128","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.semarthrit.2015.10.013","article-title":"A review of the effects of statins in systemic sclerosis","volume":"45","author":"Ladak","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib129","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/rheumatology\/kez522","article-title":"Drug initiation and escalation strategies of vasodilator therapies for Raynaud\u2019s phenomenon: can we treat to target?","volume":"59","author":"Hughes","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.semarthrit.2011.07.006","article-title":"Botulinum toxin A treatment of Raynaud\u2019s phenomenon: a review","volume":"41","author":"Iorio","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib132","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib133","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: A randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib134","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/micr.22379","article-title":"Surgical treatment of systemic sclerosis-is it justified to offer peripheral sympathectomy earlier in the disease process?","volume":"35","author":"Momeni","year":"2015","journal-title":"Microsurgery"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jor.1100150313","article-title":"Acute effects of periarterial sympathectomy on the cutaneous microcirculation","volume":"15","author":"Pollock","year":"1997","journal-title":"J Orthop Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib136","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1067\/mva.2002.123330","article-title":"Endoscopic thoracic sympathicotomy for Raynaud\u2019s phenomenon","volume":"36","author":"Matsumoto","year":"2002","journal-title":"J Vasc Surg"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib137","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","article-title":"Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions","volume":"49","author":"Amanzi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib138","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/rheumatology\/kew047","article-title":"Digital ulcers in systemic sclerosis","volume":"56","author":"Hughes","year":"2017","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib139","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5301\/jsrd.5000268","article-title":"Review of local wound management for scleroderma-associated digital ulcers","volume":"3","author":"Lebedoff","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10067-005-0016-1","article-title":"Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma)","volume":"25","author":"Ozgocmen","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib141","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib142","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib143","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib144","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the Scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.066_bib147","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"18","key":"10.1016\/j.jaad.2021.10.066_bib148","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib149","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/ket019","article-title":"Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study","volume":"52","author":"Parisi","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2014.04.028","article-title":"Effect of the endothelin type A\u2013selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study","volume":"71","author":"Chung","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib151","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jaad.2011.04.029","article-title":"Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis","volume":"65","author":"Moinzadeh","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib152","first-page":"888","article-title":"Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil","volume":"7","author":"Ambach","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib153","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3899\/jrheum.131284","article-title":"Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis","volume":"41","author":"Cutolo","year":"2014","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib154","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3899\/jrheum.160592","article-title":"Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number, fingertip blood perfusion, and clinical status in systemic sclerosis","volume":"43","author":"Trombetta","year":"2016","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib155","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1136\/annrheumdis-2015-208121","article-title":"Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry","volume":"75","author":"Matucci-Cerinic","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib156","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-014-2579-1","article-title":"Rituximab for refractory digital infarcts and ulcers in systemic sclerosis","volume":"33","author":"Khor","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib157","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/rheumatology\/keu435","article-title":"Treatment of systemic sclerosis with tocilizumab","volume":"54","author":"Fernandes das Neves","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib158","doi-asserted-by":"crossref","first-page":"510","DOI":"10.12968\/jowc.2014.23.10.510","article-title":"Scleroderma and evidence based non-pharmaceutical treatment modalities for digital ulcers: a systematic review","volume":"23","author":"Moran","year":"2014","journal-title":"J Wound Care"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib159","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ijd.13570","article-title":"Hyperbaric oxygen therapy for chronic ulcers in systemic sclerosis\u2014case series","volume":"56","author":"Mirasoglu","year":"2017","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib160","first-page":"1694","article-title":"Ischemic scleroderma wounds successfully treated with hyperbaric oxygen therapy","volume":"33","author":"Markus","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib161","doi-asserted-by":"crossref","first-page":"864","DOI":"10.5114\/aoms.2015.48152","article-title":"Botulinum toxin A in the treatment of Raynaud\u2019s phenomenon: a systematic review","volume":"4","author":"\u017bebryk","year":"2016","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib163","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SAP.0000000000000614","article-title":"Digital sympathectomy in patients with scleroderma: an overview of the practice and referral patterns and perceptions of rheumatologists","volume":"75","author":"Chiou","year":"2015","journal-title":"Ann Plast Surg"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib164","first-page":"642","article-title":"Surgery of the hand in patients with systemic sclerosis: outcomes and considerations","volume":"32","author":"Bogoch","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2009.08.002","article-title":"Systemic sclerosis: bilateral improvement of Raynaud\u2019s phenomenon with unilateral digital sympathectomy","volume":"40","author":"Wasserman","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib166","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0034-1376970","article-title":"Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis","volume":"46","author":"Bene","year":"2014","journal-title":"Handchir Mikrochir Plast Chir"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib167","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PRS.0000000000000104","article-title":"Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality","volume":"133","author":"Bank","year":"2014","journal-title":"Plast Reconstr Surg"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib168","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/keu006","article-title":"A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: A within-subject randomized trial","volume":"53","author":"Dinsdale","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib169","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0002-9343(87)90499-2","article-title":"Treatment of calcinosis universalis with low-dose warfarin","volume":"83","author":"Berger","year":"1987","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-9343(88)90128-3","article-title":"Failure of warfarin in treatment of calcinosis universalis","volume":"84","author":"Lassoued","year":"1988","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib171","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/ard.2003.014431","article-title":"Low dose warfarin treatment for calcinosis in patients with systemic sclerosis","volume":"63","author":"Cukierman","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib172","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.1780330834","article-title":"The effect of diltiazem on calcinosis in a patient with the crest syndrome","volume":"33","author":"Farah","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib173","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/ard.57.4.252","article-title":"Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression?","volume":"57","author":"Vayssairat","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib174","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/archdermatol.2011.2052","article-title":"Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009","volume":"148","author":"Balin","year":"2012","journal-title":"Arch Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.10.066_bib175","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2015-eular.4163","article-title":"SAT0469 calcinosis cutis in poly-dermatomyositis: clinical and therapeutic study","volume":"74","author":"Fredi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib176","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ced.12450","article-title":"Dosage of rituximab in systemic sclerosis: 2-year results of five cases","volume":"40","author":"Moazedi-Fuerst","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"suppl 10","key":"10.1016\/j.jaad.2021.10.066_bib177","first-page":"S737","article-title":"Long-term efficacy of rituximab in systemic sclerosis","volume":"66","author":"Narv\u00e1ez","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib178","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib179","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.62.3.267","article-title":"Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline","volume":"62","author":"Robertson","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib181","first-page":"527","article-title":"Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis","volume":"5","author":"Fuchs","year":"1986","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib182","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/bjd.15783","article-title":"Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/jpgm.JPGM_500_18","article-title":"Sodium thiosulfate dressings facilitate healing of refractory cutaneous ulcers of calcinosis cutis","volume":"65","author":"Karthik","year":"2019","journal-title":"J Postgrad Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib184","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2340\/00015555-2206","article-title":"Treatment of skin calcifications with intra-lesional injection of sodium thiosulphate: A case series","volume":"96","author":"Baumgartner-Nielsen","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2016.10.009","article-title":"Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: report of four cases","volume":"84","author":"Mageau","year":"2017","journal-title":"Jt Bone Spine"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2021.10.066_bib186","first-page":"1009.3","article-title":"AB0617 effect of sodium thiosulfate on calcinosis cutis associated with connective tissue disease","volume":"73","author":"Trysberg","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib187","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjd.14412","article-title":"Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy","volume":"175","author":"del Barrio-D\u00edaz","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib188","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1111\/ced.13782","article-title":"Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017","volume":"44","author":"Ma","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib189","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib190","first-page":"135","article-title":"Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis","volume":"28","author":"Marco Puche","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2021.10.066_bib191","first-page":"75","article-title":"[Risedronate: a possible treatment for extraosseous calcification]","volume":"15","author":"Fujii","year":"2005","journal-title":"Clin Calcium"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.066_bib192","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","article-title":"Response of dystrophic calcification to intravenous immunoglobulin","volume":"144","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib193","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/archdermatol.2008.620","article-title":"Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands","volume":"145","author":"Kalajian","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.066_bib194","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.10.066_bib195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1546-0096-11-S2-P143","article-title":"PReS-FINAL-2130-A: effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis\u2014a national cohort study UK and Ireland","volume":"11","author":"Moraitis","year":"2013","journal-title":"Pediatr Rheumatol"},{"issue":"suppl 4","key":"10.1016\/j.jaad.2021.10.066_bib196","article-title":"Abatacept as adjunct therapy for the calcinosis of juvenile dermatomyositis: A single-center experience","volume":"69","author":"DeGuzman","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2021.10.066_bib197","doi-asserted-by":"crossref","first-page":"O29","DOI":"10.1186\/1546-0096-9-S1-O29","article-title":"Effectiveness of Anti-TNF-\u03b1 agents in the treatment of refractory juvenile dermatomyositis","volume":"9","author":"Boulter","year":"2011","journal-title":"Pediatr Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.066_bib198","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s002380050122","article-title":"Microdrilling of digital calcinosis","volume":"21","author":"Fahmy","year":"1998","journal-title":"Eur J Plast Surg"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib199","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archderm.145.2.212-b","article-title":"Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome","volume":"145","author":"Saddic","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib200","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.1996.tb01166.x","article-title":"Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser","volume":"135","author":"Bottomley","year":"1996","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.066_bib201","first-page":"968","article-title":"Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser","volume":"29","author":"Chamberlain","year":"2003","journal-title":"Dermatol Surg"},{"issue":"5 suppl 100","key":"10.1016\/j.jaad.2021.10.066_bib202","first-page":"177","article-title":"Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis","volume":"34","author":"Blumhardt","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib203","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jaad.2010.12.035","article-title":"Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy","volume":"66","author":"Sultan-Bichat","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2021.10.066_bib204","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.jaad.2005.04.010","article-title":"Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy","volume":"53","author":"Sparsa","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.066_bib205","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/rheumatology\/ket275","article-title":"Canadian Scleroderma Research Group. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients","volume":"52","author":"Razykov","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.066_bib206","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/archderm.1990.01670270068011","article-title":"Elevated plasma histamine levels in systemic sclerosis (scleroderma)","volume":"126","author":"Falanga","year":"1990","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib207","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2008.07.042","article-title":"Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review","volume":"59","author":"Kroft","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.066_bib208","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s13555-016-0136-3","article-title":"Phototherapy in scleroderma","volume":"6","author":"Hassani","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib209","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5603\/FHC.2012.0027","article-title":"The role of leukotrienes in the pathogenesis of systemic sclerosis","volume":"50","author":"Chwie\u015bko-Minarowska","year":"2012","journal-title":"Folia Histochem Cytobiol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib210","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of pruritus with topically applied opiate receptor antagonist","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib211","doi-asserted-by":"crossref","first-page":"804296","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jaad.2021.10.066_bib212","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2018.08.022","article-title":"The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders","volume":"157","author":"del R\u00edo","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.066_bib213","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of Lenabasum in a Phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10103","key":"10.1016\/j.jaad.2021.10.066_bib214","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.066_bib215","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"16","key":"10.1016\/j.jaad.2021.10.066_bib216","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","article-title":"An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis","volume":"21","author":"McMahan","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.066_bib217","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2021.10.066_bib218","doi-asserted-by":"crossref","first-page":"762546","DOI":"10.1155\/2015\/762546","article-title":"Gastric antral vascular ectasia in systemic sclerosis: current concepts","volume":"2015","author":"Parrado","year":"2015","journal-title":"Int J Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.066_bib219","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/imj.12883","article-title":"Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis","volume":"45","author":"Papachristos","year":"2015","journal-title":"Intern Med J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:05:43Z","timestamp":1759273543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":217,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0190962222001918"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.10.066","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic sclerosis in adults. Part II: management and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.10.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.10.065","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}